J 2020

Is the "Common Cold" Our Greatest Ally in the Battle Against SARS-CoV-2?

CAPOOR, M. N., F. S. AHMED, A. MCDOWELL and Ondřej SLABÝ

Basic information

Original name

Is the "Common Cold" Our Greatest Ally in the Battle Against SARS-CoV-2?

Authors

CAPOOR, M. N. (guarantor), F. S. AHMED, A. MCDOWELL and Ondřej SLABÝ (203 Czech Republic, belonging to the institution)

Edition

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, LAUSANNE, FRONTIERS MEDIA SA, 2020, 2235-2988

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30102 Immunology

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 5.293

RIV identification code

RIV/00216224:14110/20:00118278

Organization unit

Faculty of Medicine

DOI

UT WoS

000603982400001

Keywords in English

SARS-CoV-2; COVID-19; T-cell; human coronaviruses; immunity; contact tracing; children

Tags

Tags

International impact, Reviewed
Změněno: 17/3/2021 14:09, Mgr. Tereza Miškechová

Abstract

V originále

The discovery of T-cell responses to SARS-CoV-2 in non-infected individuals indicates cross-reactive immune memory from prior exposure to human coronaviruses (HCoV) that cause the common cold. This raises the possibility that "immunity" could exist within populations at rates that may be higher than serology studies estimate. Besides specialized research labs, however, there is limited ability to measure HCoV CD4+ and CD8+ T-cell responses to SARS-CoV-2 infection, which currently impedes interpretation of any potential correlation between COVID-19 disease pathogenesis and the calibration of pandemic control measures. Given this limited testing ability, an alternative approach would be to exploit the large cohort of currently available data from which statistically significant associations may be generated. This would necessitate the merging of several public databases including patient and contact tracing, which could be created by relevant public health organizations. Including data from both symptomatic and asymptomatic patients in SARS-CoV-2 databases and surveillance systems could provide the necessary information to allow for more informed decisions.